LINCOLN, Neb.–(BUSINESS WIRE)–Celerion is proud to celebrate the 50th anniversary of the first clinical trial conducted at our facilities in Lincoln, Nebraska.
The company, originally called Harris Laboratories, conducted its first clinical research study in 1969, becoming one of the first organizations to offer an independent clinical research testing environment. In doing so, Harris helped to originate the contract clinical research industry. MDS Inc. acquired Harris Laboratories in 1996, and renamed the company MDS Harris, followed by MDS Pharma Services. In March 2010, Celerion acquired the early stage business from MDS Pharma Services.
“Harris Laboratories left an indelible legacy of translating science to medicine that Celerion is proud to continue to this day,” said Susan Thornton, PhD, President and CEO of Celerion. “We continue to offer innovative clinical research services for the biopharmaceutical industry by leveraging our experience, expertise, and innovative technologies, helping our clients make more informed go or no-go decisions in drug development.”
Celerion has proudly built on its legacy of innovation, science, and services. Still at the forefront of early clinical research with hundreds of innovations in early clinical studies and bioanalytical sciences, the company has offices worldwide with over 1,000 employees and over 600 beds of capacity. Celerion has proudly supported the development of many experimental and currently marketed drugs by conducting over 6,000 clinical studies globally.
About Celerion
Celerion, a global leader in early clinical research services, offers a unique combination of medical expertise, clinical operations experience, and scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path. For fifty years, Celerion has leveraged the latest operational concepts and technologies to execute safety/tolerability, pharmacokinetic, and pharmacodynamics studies in highly controlled clinic environments. These include first-in-human dose escalation, drug-drug interaction, cardiac safety, bioequivalence and bioavailability, metabolism and excretion studies, as well as pharmacokinetic evaluations in patients with impaired renal or hepatic function. Celerion offers feasibility, data management, biostatistics, clinical monitoring, and bioanalytical services. Our founding mission is to help our clients get their drugs to market quickly, so that they touch the lives of our family, friends, and people in need around the world. For more information, please visit www.celerion.com.
Contacts
Karen Wills
Executive Director, Global Marketing
+1 508 808 9825
media.inquiries@celerion.com